Andrew Clark, PhD, independent consultant in the biotech industry.
He received his Ph.D. in Neuroscience from St. Andrew’s University and was a post-doctoral research fellow in neuro-pharmacology at the University of Oxford. He worked in London as a biotechnology analyst at Baring Securities. Dr. Clark co-founded Reabourne Ltd, an investment management business focused on small capitalization technology and biotechnology companies, acting as portfolio manager. He left Reabourne in 2003 following the sale of the business.
He has held a number of non-executive directorships with life-science and investment companies which include Tepnel, Prometic Life Sciences, Lifeline Scientific and vasopharm GmbH.